Glaukos Corp

GKOS is in a Stage 2 advance, led by a dominant Lockout Rally driving forced participation and rapid upside repricing. The medium-term bias remains bullish, underpinned by clear higher highs and higher lows and rising EMAs. Short-term execution is enabled by the Lockout Rally override, allowing participation despite overbought readings, with price holding tightly above the 9/21 EMA zone.

• ↑Q1 revenue was $150.6M (+41% YoY); glaucoma franchise sales rose 58%.
• ↑CEO cites strong execution; gross margin at 84% reflects efficiency.
• ↓Q1 net loss of $0.18/share underscores ongoing unprofitability.